Ovarian Cancer Diagnostics and Therapeutics Market, Global Outlook and Forecast 2022-2028

April 2022 | 61 pages | ID: O4A4288D58C6EN
Market Monitor Global

Abstracts

Ovarian cancer is often fatal because it is usually advanced when diagnosed. Symptoms are usually absent in early stages and nonspecific in advanced stages.The goal of treatment for ovarian cancer is to surgically remove as much of the cancer as possible through the debulking and then to provide what is called adjuvant, or additional therapy, such as chemotherapy, to kill any possibly remaining cancer cells in the body.

This report contains market size and forecasts of Ovarian Cancer Diagnostics and Therapeutics in Global, including the following market information:

Global Ovarian Cancer Diagnostics and Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Ovarian Cancer Diagnostics and Therapeutics market was valued at 1863.4 million in 2021 and is projected to reach US$ 2651.5 million by 2028, at a CAGR of 5.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Diagnosis Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ovarian Cancer Diagnostics and Therapeutics include Astrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Glaxosmithkline, Johnson & Johnson, Kazia Therapeutics and Siemens Healthineers, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ovarian Cancer Diagnostics and Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ovarian Cancer Diagnostics and Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Ovarian Cancer Diagnostics and Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Diagnosis
• Therapeutics

Global Ovarian Cancer Diagnostics and Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Ovarian Cancer Diagnostics and Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Medical Research Institute
• Pharmaceuticals Companies
• Other

Global Ovarian Cancer Diagnostics and Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Ovarian Cancer Diagnostics and Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Ovarian Cancer Diagnostics and Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Ovarian Cancer Diagnostics and Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Astrazeneca
• Boehringer Ingelheim
• Bristol Myers Squibb
• Eli Lilly
• F. Hoffman-La Roche
• Glaxosmithkline
• Johnson & Johnson
• Kazia Therapeutics
• Siemens Healthineers
• MSD
• Clovis Oncology
• Pfizer
• Merck

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Ovarian Cancer Diagnostics and Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Ovarian Cancer Diagnostics and Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL OVARIAN CANCER DIAGNOSTICS AND THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Ovarian Cancer Diagnostics and Therapeutics Market Size: 2021 VS 2028
2.2 Global Ovarian Cancer Diagnostics and Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Ovarian Cancer Diagnostics and Therapeutics Players in Global Market
3.2 Top Global Ovarian Cancer Diagnostics and Therapeutics Companies Ranked by Revenue
3.3 Global Ovarian Cancer Diagnostics and Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Ovarian Cancer Diagnostics and Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Ovarian Cancer Diagnostics and Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Ovarian Cancer Diagnostics and Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Ovarian Cancer Diagnostics and Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Ovarian Cancer Diagnostics and Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Ovarian Cancer Diagnostics and Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Diagnosis
  4.1.3 Therapeutics
4.2 By Type - Global Ovarian Cancer Diagnostics and Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Ovarian Cancer Diagnostics and Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Medical Research Institute
  5.1.4 Pharmaceuticals Companies
  5.1.5 Other
5.2 By Application - Global Ovarian Cancer Diagnostics and Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Ovarian Cancer Diagnostics and Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2028
  6.3.2 US Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.3.3 Canada Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2028
  6.4.2 Germany Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.4.3 France Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.4.5 Italy Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.4.6 Russia Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2028
  6.5.2 China Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.5.3 Japan Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.5.6 India Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.7.3 Israel Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028
  6.7.5 UAE Ovarian Cancer Diagnostics and Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Astrazeneca
  7.1.1 Astrazeneca Corporate Summary
  7.1.2 Astrazeneca Business Overview
  7.1.3 Astrazeneca Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.1.4 Astrazeneca Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Astrazeneca Key News
7.2 Boehringer Ingelheim
  7.2.1 Boehringer Ingelheim Corporate Summary
  7.2.2 Boehringer Ingelheim Business Overview
  7.2.3 Boehringer Ingelheim Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.2.4 Boehringer Ingelheim Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Boehringer Ingelheim Key News
7.3 Bristol Myers Squibb
  7.3.1 Bristol Myers Squibb Corporate Summary
  7.3.2 Bristol Myers Squibb Business Overview
  7.3.3 Bristol Myers Squibb Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.3.4 Bristol Myers Squibb Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Bristol Myers Squibb Key News
7.4 Eli Lilly
  7.4.1 Eli Lilly Corporate Summary
  7.4.2 Eli Lilly Business Overview
  7.4.3 Eli Lilly Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.4.4 Eli Lilly Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Eli Lilly Key News
7.5 F. Hoffman-La Roche
  7.5.1 F. Hoffman-La Roche Corporate Summary
  7.5.2 F. Hoffman-La Roche Business Overview
  7.5.3 F. Hoffman-La Roche Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.5.4 F. Hoffman-La Roche Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 F. Hoffman-La Roche Key News
7.6 Glaxosmithkline
  7.6.1 Glaxosmithkline Corporate Summary
  7.6.2 Glaxosmithkline Business Overview
  7.6.3 Glaxosmithkline Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.6.4 Glaxosmithkline Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Glaxosmithkline Key News
7.7 Johnson & Johnson
  7.7.1 Johnson & Johnson Corporate Summary
  7.7.2 Johnson & Johnson Business Overview
  7.7.3 Johnson & Johnson Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.7.4 Johnson & Johnson Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Johnson & Johnson Key News
7.8 Kazia Therapeutics
  7.8.1 Kazia Therapeutics Corporate Summary
  7.8.2 Kazia Therapeutics Business Overview
  7.8.3 Kazia Therapeutics Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.8.4 Kazia Therapeutics Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Kazia Therapeutics Key News
7.9 Siemens Healthineers
  7.9.1 Siemens Healthineers Corporate Summary
  7.9.2 Siemens Healthineers Business Overview
  7.9.3 Siemens Healthineers Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.9.4 Siemens Healthineers Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Siemens Healthineers Key News
7.10 MSD
  7.10.1 MSD Corporate Summary
  7.10.2 MSD Business Overview
  7.10.3 MSD Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.10.4 MSD Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 MSD Key News
7.11 Clovis Oncology
  7.11.1 Clovis Oncology Corporate Summary
  7.11.2 Clovis Oncology Business Overview
  7.11.3 Clovis Oncology Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.11.4 Clovis Oncology Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.11.5 Clovis Oncology Key News
7.12 Pfizer
  7.12.1 Pfizer Corporate Summary
  7.12.2 Pfizer Business Overview
  7.12.3 Pfizer Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.12.4 Pfizer Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.12.5 Pfizer Key News
7.13 Merck
  7.13.1 Merck Corporate Summary
  7.13.2 Merck Business Overview
  7.13.3 Merck Ovarian Cancer Diagnostics and Therapeutics Major Product Offerings
  7.13.4 Merck Ovarian Cancer Diagnostics and Therapeutics Revenue in Global Market (2017-2022)
  7.13.5 Merck Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Ovarian Cancer Diagnostics and Therapeutics Market Opportunities & Trends in Global Market
Table 2. Ovarian Cancer Diagnostics and Therapeutics Market Drivers in Global Market
Table 3. Ovarian Cancer Diagnostics and Therapeutics Market Restraints in Global Market
Table 4. Key Players of Ovarian Cancer Diagnostics and Therapeutics in Global Market
Table 5. Top Ovarian Cancer Diagnostics and Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Ovarian Cancer Diagnostics and Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Ovarian Cancer Diagnostics and Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Ovarian Cancer Diagnostics and Therapeutics Product Type
Table 9. List of Global Tier 1 Ovarian Cancer Diagnostics and Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ovarian Cancer Diagnostics and Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Ovarian Cancer Diagnostics and Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Ovarian Cancer Diagnostics and Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Ovarian Cancer Diagnostics and Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Ovarian Cancer Diagnostics and Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Astrazeneca Corporate Summary
Table 31. Astrazeneca Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 32. Astrazeneca Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Boehringer Ingelheim Corporate Summary
Table 34. Boehringer Ingelheim Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 35. Boehringer Ingelheim Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Bristol Myers Squibb Corporate Summary
Table 37. Bristol Myers Squibb Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 38. Bristol Myers Squibb Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Eli Lilly Corporate Summary
Table 40. Eli Lilly Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 41. Eli Lilly Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. F. Hoffman-La Roche Corporate Summary
Table 43. F. Hoffman-La Roche Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 44. F. Hoffman-La Roche Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Glaxosmithkline Corporate Summary
Table 46. Glaxosmithkline Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 47. Glaxosmithkline Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Johnson & Johnson Corporate Summary
Table 49. Johnson & Johnson Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 50. Johnson & Johnson Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Kazia Therapeutics Corporate Summary
Table 52. Kazia Therapeutics Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 53. Kazia Therapeutics Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Siemens Healthineers Corporate Summary
Table 55. Siemens Healthineers Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 56. Siemens Healthineers Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. MSD Corporate Summary
Table 58. MSD Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 59. MSD Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Clovis Oncology Corporate Summary
Table 61. Clovis Oncology Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 62. Clovis Oncology Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. Pfizer Corporate Summary
Table 64. Pfizer Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 65. Pfizer Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Merck Corporate Summary
Table 67. Merck Ovarian Cancer Diagnostics and Therapeutics Product Offerings
Table 68. Merck Ovarian Cancer Diagnostics and Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Ovarian Cancer Diagnostics and Therapeutics Segment by Type in 2021
Figure 2. Ovarian Cancer Diagnostics and Therapeutics Segment by Application in 2021
Figure 3. Global Ovarian Cancer Diagnostics and Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Ovarian Cancer Diagnostics and Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Ovarian Cancer Diagnostics and Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Ovarian Cancer Diagnostics and Therapeutics Revenue in 2021
Figure 8. By Type - Global Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Ovarian Cancer Diagnostics and Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Astrazeneca Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Boehringer Ingelheim Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bristol Myers Squibb Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Eli Lilly Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. F. Hoffman-La Roche Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Glaxosmithkline Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Johnson & Johnson Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Kazia Therapeutics Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Siemens Healthineers Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. MSD Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Clovis Oncology Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Pfizer Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Merck Ovarian Cancer Diagnostics and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)